Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A known ✓ | P08913 | 2/20 | 0.42 |
| ▸ | ADRA2B known ✓ | P18089 | 2/20 | 0.42 |
| ▸ | ADRA2C known ✓ | P18825 | 2/20 | 0.42 |
| ▸ | GAA known ✓ | P10253 | 1/20 | 0.40 |
| ▸ | FDPS | P14324 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 8/20 | 0.44 |
| ▸ | NPC1 | O15118 | 7/20 | 0.44 |
| ▸ | CASP3 | P42574 | 1/20 | 0.44 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL246507 | 0.98 | — | — | |
| SCHEMBL29505965 | 0.98 | — | — | |
| SCHEMBL11158370 | 0.81 | NPC1 (0.44) | FDPSRAB9ANPC1ALDH1A1MEN1 | |
| SCHEMBL355054 | 0.78 | ALDH1A1 (0.50) | FDPSRAB9ANPC1CASP3SENP7 | |
| Hydrochloric Acid SCHEMBL29168252 | 0.77 | HCAR3 (0.47) | FDPSRAB9ANPC1CASP3SENP7 | |
| SCHEMBL182965 | 0.74 | — | — | |
| SCHEMBL30057293 | 0.74 | — | — | |
| Hydrochloric Acid SCHEMBL11640484 | 0.74 | PTGS1 (0.41) | RAB9AALDH1A1MEN1KMT2AADRA2A | |
| SCHEMBL8503999 | 0.74 | — | — | |
| SCHEMBL8503997 | 0.74 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4543890-A1 | USP1 INHIBITORS AND USES THEREOF | Forma Therapeutics, Inc. (US) | 2025-04-30 | — | — | EP | disclosed |
| CN-119731178-A | USP1 inhibitors and uses thereof | 福马治疗有限公司 | 2025-03-28 | — | — | CN | disclosed |
| CN-119552120-A | Pyrazole and imidazole compounds for inhibiting IL-17 and rory | 里亚塔医药公司 | 2025-03-04 | — | — | CN | disclosed |
| CN-112654610-B | Pyrazole and imidazole compounds for inhibiting IL-17 and rory | 里亚塔医药公司 | 2024-12-24 | — | — | CN | disclosed |
| US-20240360084-A1 | PYRAZOLE AND IMIDAZOLE COMPOUNDS FOR INHIBITION OF IL-17 AND RORGAMMA | REATA PHARMACEUTICALS INC (US) | 2024-10-31 | — | — | US | disclosed |
| US-11993574-B2 | Pyrazole and imidazole compounds for inhibition of IL-17 and RORgamma | REATA PHARMACEUTICALS, INC (US) | 2024-05-28 | — | — | US | disclosed |
| WO-2023250084-A1 | USP1 INHIBITORS AND USES THEREOF | FORMA THERAPEUTICS, INC. (US) | 2023-12-28 | — | — | WO | disclosed |
| CN-108840894-B | 4' -hydrazone group substituted avermectin B2a/B2B derivative and salt thereof | 河北威远生物化工有限公司 | 2022-03-11 | — | — | CN | disclosed |
| US-20210292281-A1 | PYRAZOLE AND IMIDAZOLE COMPOUNDS FOR INHIBITION OF IL-17 AND RORGAMMA | REATA PHARMACEUTICALS, INC. (US) | 2021-09-23 | — | — | US | disclosed |
| EP-3807265-A1 | PYRAZOLE AND IMIDAZOLE COMPOUNDS FOR INHIBITION OF IL-17 AND RORGAMMA | Reata Pharmaceuticals, Inc. (US) | 2021-04-21 | — | — | EP | disclosed |
| CN-112654610-A | Pyrazole and imidazole compounds for inhibiting IL-17 and ROR gamma | 里亚塔医药公司 | 2021-04-13 | — | — | CN | disclosed |
| US-20160304507-A1 | SUBSTITUTED PYRAZOLE COMPOUNDS AS CRAC MODULATORS | LUPIN LIMITED (IN) | 2016-10-20 | — | — | US | disclosed |
| US-9409898-B2 | Substituted pyrazole compounds as CRAC modulators | LUPIN LIMITED (IN) | 2016-08-09 | — | — | US | disclosed |
| US-20150111925-A1 | SUBSTITUTED PYRAZOLE COMPOUNDS AS CRAC MODULATORS | LUPIN LIMITED (IN) | 2015-04-23 | — | — | US | disclosed |
| EP-2844656-A1 | SUBSTITUTED PYRAZOLE COMPOUNDS AS CRAC MODULATORS | Lupin Limited (IN) | 2015-03-11 | — | — | EP | disclosed |
| WO-2013164773-A1 | SUBSTITUTED PYRAZOLE COMPOUNDS AS CRAC MODULATORS | LUPIN LIMITED (IN) | 2013-11-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150111925-A1 | SUBSTITUTED PYRAZOLE COMPOUNDS AS CRAC MODULATORS | ORAI1, RYR2, RYR1 | ADRA2A 209/4885ADRA2B 198/4885ADRA2C 88/4885 |
| US-20210292281-A1 | PYRAZOLE AND IMIDAZOLE COMPOUNDS FOR INHIBITION OF IL-17 AND RORGAMMA | RORC, RORB, RORA | ADRA2A 1896/4885ADRA2B 710/4885ADRA2C 658/4885 |
| US-20240360084-A1 | PYRAZOLE AND IMIDAZOLE COMPOUNDS FOR INHIBITION OF IL-17 AND RORGAMMA | RORC, RORB, RORA | ADRA2A 1896/4885ADRA2B 710/4885ADRA2C 658/4885 |
| US-11993574-B2 | Pyrazole and imidazole compounds for inhibition of IL-17 and RORgamma | RORC, RORB, RORA | ADRA2A 1896/4885ADRA2B 710/4885ADRA2C 658/4885 |
| US-20160304507-A1 | SUBSTITUTED PYRAZOLE COMPOUNDS AS CRAC MODULATORS | ORAI1, RYR2, RYR1 | ADRA2A 209/4885ADRA2B 198/4885ADRA2C 88/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.